NEW YORK, Nov. 22 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. announced today that its wholly-owned subsidiary, Biomedical Diagnostics, LLC (Biomedical) in Ann Arbor, MI, has signed a development agreement with Harlan Bioproducts for Science, Inc. (Harlan).
Harlan will assist Biomedical in the research and development of new monoclonal antibodies for potential use in Biomedical's Mammastatin Serum Assay (MSA). Harlan provides custom antibody production services to research institutions and to the biotechnology and pharmaceutical industries. Harlan is one of the country's largest custom antibody services companies and is part of Harlan Industries, Inc., one of the world's largest suppliers of research related products and services. All of Harlan's antibody production is performed in cGMP FDA-registered or USDA-licensed facilities.
The MSA is a blood test that assesses women's breast health. In scientific correlation studies women who have a high test result have been shown to have a lower risk of breast cancer than women who have a low test result. The MSA test is currently available to physicians through ARUP Laboratories in Salt Lake City, Utah, or directly through Biomedical's laboratory services.
Jim Arthurs, president of Biomedical Diagnostics stated, "We are pleased to have this development agreement with a company of Harlan's reputation. New antibodies could allow Biomedical to advance its current technology and implement enhancements to the MSA, ultimately making the test more practical for physicians."
More information about Biomedical Diagnostics and the MSA test can be found at www.bio-diagnostics.com. More information about Harlan Bioproducts can be found at www.hbps.com.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com Aurelius Consulting Group: (800) 644-6297, info@runonideas.com, www.runonideas.com
Genesis Bioventures, Inc.CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com,www.gnsbio.com; Aurelius Consulting Group: (800) 644-6297,info@runonideas.com, www.runonideas.com
